| Budget Amount *help |
¥17,290,000 (Direct Cost: ¥13,300,000、Indirect Cost: ¥3,990,000)
Fiscal Year 2023: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2022: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2021: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
|
|---|
| Outline of Final Research Achievements |
Mouse monoclonal antibodies with cross-neutralizing activity against multiple orthomarburgviruses (Marburg virus and Ravn virus) were generated. By identification of the amino acid substitutions of escape mutants for each antibody and detailed epitope analysis on the viral surface glycoprotein, these antibodies are predicted to inhibit membrane fusion between the cell membrane and the viral envelope or to inhibit binding with host cell receptors. We also determined the amino acid sequences of the variable regions of these neutralizing antibodies and succeeded in creating human-mouse chimeric antibodies. Furthermore, the therapeutic effects of administration of the produced antibodies were confirmed using a mouse model infected with Marburg virus.
|
